Karyopharm Therapeutics Inc (KPTI)
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
📈 **POSITIVE** • Medium confidence analysis (67%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General